Susquehanna International Group
YMAB

Susquehanna International Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Susquehanna International Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,800
Closed -$436K – 13390
2024
Q1 		$436K Buy
+26,800
New +$361K ﹤0.01% 8847
2023
Q1 		– Sell
-11,000
Closed -$53.7K – 13619
2022
Q4 		$53.7K Sell
11,000
-46,700
-81% -$339K ﹤0.01% 11352
2022
Q3 		$832K Sell
57,700
-2,100
-4% -$34.8K ﹤0.01% 7113
2022
Q2 		$905K Buy
59,800
+28,500
+91% +$333K ﹤0.01% 6773
2022
Q1 		$372K Buy
+31,300
New +$321K ﹤0.01% 9728

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's YMAB Position: Q3 2025 in Review

Susquehanna International Group sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 51,090 shares — an estimated $230K sold.

Susquehanna International Group first reported a position in YMAB in Q3 2019 and held it in 21 quarters. The position peaked at $759K in Q3 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Susquehanna International Group reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 51,090 Y-mAbs Therapeutics shares in Q3 2025, an estimated $230K.
  • Susquehanna International Group first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 21 quarters.
  • Susquehanna International Group's Y-mAbs Therapeutics position peaked at $759K in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.